These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 2306738)
1. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Masuda H; Tanaka T; Matsuda H; Kusaba I Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738 [TBL] [Abstract][Full Text] [Related]
2. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line. Tanaka T; Masuda H; Naito M; Tamai H Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308 [TBL] [Abstract][Full Text] [Related]
3. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W; Chaney SG Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361 [TBL] [Abstract][Full Text] [Related]
4. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504 [TBL] [Abstract][Full Text] [Related]
5. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973 [TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897 [TBL] [Abstract][Full Text] [Related]
7. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts. Roberts JJ; Friedlos F Cancer Res; 1987 Jan; 47(1):31-6. PubMed ID: 3791217 [TBL] [Abstract][Full Text] [Related]
8. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. Yoshida M; Khokhar AR; Siddik ZH Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968 [TBL] [Abstract][Full Text] [Related]
9. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. Kido Y; Khokhar AR; al-Baker S; Siddik ZH Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629 [TBL] [Abstract][Full Text] [Related]
10. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681 [TBL] [Abstract][Full Text] [Related]
11. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Andrews PA; Velury S; Mann SC; Howell SB Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000 [TBL] [Abstract][Full Text] [Related]
12. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Shellard SA; Hosking LK; Hill BT Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800 [TBL] [Abstract][Full Text] [Related]
13. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients. Terheggen PM; Dijkman R; Begg AC; Dubbelman R; Floot BG; Hart AA; den Engelse L Cancer Res; 1988 Oct; 48(19):5597-603. PubMed ID: 3046743 [TBL] [Abstract][Full Text] [Related]
14. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells. Fram RJ; Woda BA; Wilson JM; Robichaud N Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559 [TBL] [Abstract][Full Text] [Related]
15. Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs. Vendrik CP; de Jong WH; Van der Minnen AC; Fichtinger-Schepman AM; Steerenberg PA; Schornagel JH Anticancer Res; 1990; 10(2A):447-52. PubMed ID: 2346318 [TBL] [Abstract][Full Text] [Related]
16. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line. McLaughlin K; Stephens I; McMahon N; Brown R Cancer Res; 1991 Apr; 51(8):2242-5. PubMed ID: 1901242 [TBL] [Abstract][Full Text] [Related]
17. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Masuda H; Ozols RF; Lai GM; Fojo A; Rothenberg M; Hamilton TC Cancer Res; 1988 Oct; 48(20):5713-6. PubMed ID: 3139281 [TBL] [Abstract][Full Text] [Related]
18. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422 [TBL] [Abstract][Full Text] [Related]
19. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660 [TBL] [Abstract][Full Text] [Related]
20. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. Waud WR Cancer Res; 1987 Dec; 47(24 Pt 1):6549-55. PubMed ID: 3677093 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]